Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Summary
NIH ClinicalTrials.gov registered a new clinical trial (NCT07548801) investigating cerebellar transcranial direct current stimulation (ctDCS) for Parkinson's Disease motor and non-motor symptoms. The single-arm study will enroll participants completing quality-of-life, anxiety, and depression questionnaires, with motor assessment via MDS-UPDRS Part III and cognitive evaluation via CCAS at baseline and Day 10 following 8 days of at-home ctDCS stimulation. A one-month follow-up will reassess quality of life and PD-related symptoms. Anticipated study completion is April 2026.
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH ClinicalTrials.gov added a new clinical trial registration for NCT07548801, a Phase N/A study evaluating cerebellar transcranial direct current stimulation (ctDCS) as a potential treatment for both motor and non-motor symptoms in Parkinson's Disease patients. The study involves questionnaires on quality of life, anxiety, depression, and PD symptoms, with motor impairment assessed using the MDS-UPDRS Part III and cognitive impairment measured via the Cerebellar Cognitive Affective Syndrome scale.
Affected parties include Parkinson's Disease patients seeking investigational home-based treatment options and researchers studying non-invasive neuromodulation therapies. Healthcare providers offering or considering ctDCS should note this trial as an emerging evidence source for cerebellar stimulation in PD management.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
N/A NCT07548801 Kind: NA Apr 23, 2026
Abstract
Background & Rationale:
Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.
Study Procedures:
Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.
On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.
Objective:
Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
Conditions: PARKINSON DISEASE (Disorder)
Interventions: cTDCS, cTDCS
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.